IBS linked to nearly 3x higher Sjogren risk in 920,000-patient study

For decades, being told your gut problem is "functional" has worked as a dismissal: nothing visibly wrong, nothing structurally damaged, learn to manage it. A new analysis of nearly a million matched patient records suggests that dismissal was premature. People diagnosed with irritable bowel syndrome were later diagnosed with systemic rheumatic diseases at substantially higher rates than closely matched people without IBS, with the sharpest signal in Sjögren disease. If you have IBS and have quietly wondered whether the dry eyes or the joint stiffness are connected, this study is about you.

Key Takeaways

• In 459,966 IBS patients matched one-to-one against non-IBS controls, IBS preceded higher rates of every rheumatic disease examined, led by Sjögren disease (HR 2.84) and ankylosing spondylitis (HR 2.57).
• Men with IBS showed a Sjögren hazard of 6.44, higher than women's 4.05, inverting the usual pattern in a disease that overwhelmingly affects women.
• This is electronic health record data. It cannot show that IBS causes autoimmune disease, and the authors' own comparator analysis suggests extra doctor visits explain part of the effect.
• The practical takeaway is not panic, it is not letting new dry eye, dry mouth or persistent joint symptoms get filed under "it's just my IBS."

IBS preceded higher rates of eight rheumatic diseases

People with irritable bowel syndrome were later diagnosed with systemic rheumatic diseases significantly more often than matched people without IBS, across all eight conditions studied. That is the finding of a global federated cohort analysis published in Frontiers in Immunology by Shuo-Yan Gau, Meng-Che Wu and colleagues, drawing on the TriNetX network of anonymized health records from more than 150 healthcare organizations.

Among connective tissue diseases (autoimmune conditions attacking the tissues that support organs and joints), Sjögren disease carried the highest hazard ratio at 2.84 (95% CI 2.60 to 3.12), followed by systemic sclerosis at 2.09 (1.64 to 2.67), systemic lupus erythematosus at 1.84 (1.65 to 2.04) and dermatomyositis or polymyositis at 1.52 (1.11 to 2.07). Among inflammatory arthritis outcomes, ankylosing spondylitis led at 2.57 (2.22 to 2.98), then psoriatic arthritis at 2.03 (1.80 to 2.29), rheumatoid arthritis at 1.42 (1.28 to 1.56) and gout at 1.34 (1.27 to 1.42).

A hazard ratio is the relative rate at which new diagnoses appeared in one group versus the other. In absolute terms the numbers stay small: 1,702 IBS patients (0.4%) developed Sjögren disease versus 638 controls (0.1%). A meaningful relative shift on a low baseline, not a common outcome.

Why men with IBS are the unexpected group here

The sex-stratified results are the most surprising part, because autoimmune disease usually skews heavily female and here the male signal was stronger. In separately matched male and female cohorts, men with IBS had a Sjögren hazard of 6.44 (4.51 to 9.20) against 4.05 (3.70 to 4.44) in women. Men were essentially level with women for lupus (3.02 versus 3.04) and lower for rheumatoid arthritis (1.59 versus 2.18) and ankylosing spondylitis (3.37 versus 4.02), so the inversion is specific to Sjögren rather than general.

That matters clinically, because Sjögren disease is nine times more common in women than men according to the National Institute of Dental and Craniofacial Research, affecting an estimated 1 to 4 million Americans, most diagnosed after age 50. A condition clinicians are primed to look for in women is exactly the kind that gets missed in men. A man with IBS who develops persistent dry eyes and dry mouth sits at the intersection of two diagnoses each easy to wave off.

One caveat on those numbers: the sex-stratified analyses were re-matched separately within each sex, which is why several exceed the overall hazard ratio. They are not directly comparable to the primary estimates.

Propensity matching and negative controls, on 459,966 patients

The study's methodological strength is its scale combined with active comparator and negative control analyses. Starting from 459,966 adults with IBS and 6,283,812 controls, the researchers used one-to-one propensity score matching (a technique pairing each patient with a statistical near-twin) on age, sex, race, body mass index, hypertension, hyperlipidemia, diabetes, psychiatric conditions and substance use disorders, retaining 459,966 patients in each arm. Matched cohorts averaged 44.7 years old and were 72.1% female. Patients with inflammatory bowel disease, prior malignancy or pre-existing rheumatic disease were excluded.

Two checks deserve credit. The team ran negative control outcomes, conditions that should show no association if the analysis is sound: rickettsioses came back at HR 0.93 (0.73 to 1.18) and tuberculosis at 0.86 (0.73 to 1.00), both null. They also tested alternative IBS definitions, follow-up windows of one and five years, washout periods extended to 24 and 36 months, and exclusion of IBS mimics such as celiac disease and microscopic colitis. The direction held throughout, and a parallel analysis in the TriNetX US network was broadly consistent.

What an IBS diagnosis should and should not change

An IBS diagnosis is not a reason to request autoimmune screening, but it is a reason to stop attributing every new symptom to the gut. The symptoms worth flagging are the ones outside the digestive tract: dry eyes or dry mouth persisting for months, joint pain and swelling worse in the morning and lasting more than half an hour, unexplained rashes, and inflammatory back pain in a younger adult that improves with movement rather than rest.

IBS affects about 12 percent of people in the United States and is defined by the National Institute of Diabetes and Digestive and Kidney Diseases as occurring without visible signs of damage or disease in the digestive tract, now classed among disorders of gut-brain interaction. Even a hazard ratio near 3 on a 0.1% baseline event rate means the overwhelming majority of people with IBS will never develop Sjögren disease. Nothing here justifies anxiety, screening tests or a change in IBS management.

What it does justify is precision in the exam room. If you have IBS and new non-digestive symptoms, raise them as a separate complaint rather than a footnote to your gut history.

Surveillance bias remains a live alternative explanation

The biggest limitation is that this design cannot separate a real biological link from the effect of simply seeing more doctors. People with IBS visit healthcare systems more often, and more visits mean more chances to be tested and diagnosed. The authors confronted this with active comparator analyses using hernia and gastritis or duodenitis patients, groups with elevated healthcare contact but no gut-immune hypothesis. Associations attenuated but persisted, particularly for Sjögren disease, ankylosing spondylitis and psoriatic arthritis. The authors state plainly that the attenuation in the hernia comparator "suggests increased healthcare utilization partially contributed."

Reverse causation is the second problem. Sjögren disease and systemic sclerosis can smoulder for years with vague symptoms, gut dysmotility among them. Some patients may have had early undiagnosed autoimmune disease labelled IBS first. Extended washout periods only partly address this, as the authors acknowledge.

Beyond that, diagnoses came from routine billing codes rather than adjudicated criteria, IBS subtype was unavailable, disease severity and serology could not be assessed, competing-risk analysis was not possible within the TriNetX interface, and residual confounding from genetics and over-the-counter medication use cannot be excluded. The study was partially supported by the Taichung Veterans General Hospital research foundation, with no commercial conflicts declared.

What would actually settle the question

Resolving causation requires prospective cohorts that measure immune markers before symptoms appear, not more record-linkage studies. The useful next step would be following people with new IBS diagnoses over years while collecting autoantibody panels, inflammatory markers and stool microbiome sequencing, so biology precedes diagnosis in the data rather than trailing it. Mechanistic work on intestinal barrier permeability and mucosal immune activation would supply the missing middle, which this dataset does not contain at all.

Realistically that is a decade of work. In the meantime, the reasonable use of this finding is as a prompt for clinical attention rather than a claim about cause.

Common Questions

Does IBS cause autoimmune disease? This study cannot answer that. It shows an association in health records after statistical matching, and the authors explicitly state the observational design precludes causal conclusions. Surveillance bias and reverse causation both remain plausible explanations for part of the effect.

How much higher is my actual risk if I have IBS? In absolute terms, small. Sjögren disease occurred in 0.4% of the IBS group versus 0.1% of controls over up to ten years of follow-up, meaning more than 99% of people with IBS in this cohort did not develop it.

Why would men with IBS have higher Sjögren risk than women? The study does not explain it, and the sex-stratified cohorts were matched separately, so those estimates are not directly comparable to the main analysis. Detection bias is one candidate, since Sjögren disease is diagnosed far more often in women and may be under-recognized in men.

Should I ask for an autoimmune blood test because I have IBS? Not on the basis of IBS alone. Testing makes sense when you have specific symptoms outside the gut, such as months of dry eyes and dry mouth, swollen joints, or inflammatory back pain.

References

Shuo-Yan Gau, Yu-Jung Su, Shih-Chi Yang, et al. (2026). Risk of systemic rheumatic diseases in people with irritable bowel syndrome: a global-federated cohort analysis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1779191